China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with US-based Incyte Pharmaceuticals Inc., (NASDAQ: INCY) focused on Incyte’s Opzelura (ruxolitinib) cream. As per the agreement, which will initially last 10 years, the Chinese firm will take exclusive research and development (R&D), regulatory filing, and commercialization rights to the products in Greater China (including mainland China, Hong Kong, Macao, and Taiwan) and 11 Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor Leste and Brunei), alongside non-exclusive manufacturing rights for the said regions. No financial specifics were disclosed.
Opzelura: US Approvals and Indications
Opzelura, a topical JAK inhibitor for external use, was approved in the US for use as a short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in patients aged 12 years and above with non-immune hypofunction who cannot be adequately controlled by traditional topical prescription therapy in September last year. The drug, being assessed in other immune-mediated skin diseases, such as lichen planus and lichen sclerosus, obtained another market nod in the US as a local treatment of non-segmental vitiligo in patients aged 12 years and above in July this year.-Fineline Info & Tech
